NCT07144280 - A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

680

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

March 10, 2028

Study Completion Date

March 10, 2032

Conditions

Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Carcinoma

Interventions

DRUG

PF-08046054

"Antibody Drug Conjugate~Participants will receive PF-08046054, administered as an IV infusion."

DRUG

Docetaxel monotherapy

Participants will receive Docetaxel, administered as an IV infusion.

Trial Locations (6)

NOT_YET_RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

NOT_YET_RECRUITING

White Plains Hospital, White Plains

NOT_YET_RECRUITING

Taipei Veterans General Hospital, Taipei

RECRUITING

Shanghai East Hospital, Shanghai

NOT_YET_RECRUITING

Mie Chuo Medical Center, Tsu

NOT_YET_RECRUITING

Ad-Vance Medical Research, Ponce